174 Small Molecule CRO and CDMO vendors

What does it take to develop and manufacture a Small Molecule drug?

Small molecules are the oldest and best understood drug class, and that maturity cuts both ways. The science is well trodden, so there is a deep bench of CROs and CDMOs who can run any single piece of the work. The flip side is that a small molecule program touches an unusually long chain of distinct skills, and the vendor who is brilliant at one of them is often mediocre at the next. You rarely buy a small molecule program from one shop. You assemble it.

On the discovery and preclinical side, the work runs through medicinal and synthetic chemistry (analog design, route scouting, custom synthesis, research-scale batches), in vitro pharmacology and selectivity panels, then the ADME and DMPK package: solubility, permeability, microsomal and hepatocyte stability, CYP inhibition and induction, plasma protein binding, and in vivo PK across species. Toxicology follows, exploratory first, then the GLP studies that support the IND. Each of these is its own specialty with its own equipment and its own regulatory expectations.

Where specialist small molecule CDMOs really separate from generalists is on the chemistry, manufacturing, and controls side. Making a clean, scalable API is harder than it looks. You need process chemists who can take a medicinal-chemistry route that worked at gram scale and redesign it for kilos and then tonnes, solid-state scientists who screen polymorphs and salts before a bad crystal form ruins a formulation, and analytical teams who can develop and validate methods, control genotoxic impurities (the nitrosamine problem is the obvious recent example), and write the CMC sections a regulator will actually accept. A generalist CDMO that mostly does fill-finish or biologics will struggle here. A high-potency (HPAPI) compound narrows the field further, because containment to OEL bands is a real capital investment that not every site has made.

How do you choose a CRO or CDMO for Small Molecule?

The right filter is fit to your specific chemistry and stage, not the size of the logo. A shop that excels at early discovery chemistry is not automatically the one you want carrying a process into GMP, and a large commercial CDMO may not want your 50 kg clinical campaign. Match the vendor to the exact job, and confirm the people who would actually run your work have done that chemistry before. Run this checklist before you sign anything:

• Relevant platform and track record: ask for case studies in your reaction type and molecular class (chiral synthesis, organometallic catalysis, continuous flow, hazardous chemistry), not generic capability slides. References from programs that reached the clinic carry more weight than capacity claims.
• GxP status matched to the stage: research-grade is fine for discovery chemistry and exploratory ADME, but IND-enabling tox must be GLP and any clinical API must be GMP. Confirm the specific site holds the certification, and check inspection history with the FDA and EMA if you can.
• Analytical and solid-form capability: method development and validation, impurity and genotoxic-impurity control, polymorph and salt screening, and reference-standard qualification. Weak analytics is where small molecule CMC quietly falls apart.
• Capacity and scale that matches your trajectory: reactor sizes, the realistic step from grams to kilos to commercial, and whether the same vendor can carry you through scale-up so you are not re-validating a route at a new site mid-program. For potent compounds, verify HPAPI containment to the right OEL band.
• Regulatory experience: a documented history of supporting INDs and NDAs, writing CMC modules, handling impurity qualification, and surviving inspections. Ask how many of their programs have been referenced in approved filings.
• IP and confidentiality: clear ownership of the route, process improvements, and any vendor-developed know-how, plus how compounds, batch records, and analytical data transfer to you. Settle this in writing before work starts, because the process IP can be as valuable as the molecule.